[
    {
        "text": "This episode was filmed on May 29th, 2020.",
        "start": 0.0,
        "duration": 2.8
    },
    {
        "text": "If we have more recent episodes on the COVID-19\npandemic,",
        "start": 2.8,
        "duration": 2.66
    },
    {
        "text": "we’ll include them in the description.",
        "start": 5.46,
        "duration": 1.36
    },
    {
        "text": "[♪ INTRO]",
        "start": 6.82,
        "duration": 3.22
    },
    {
        "text": "Researchers have been working on vaccine candidates\nfor COVID-19",
        "start": 10.04,
        "duration": 2.9
    },
    {
        "text": "for months now.",
        "start": 12.94,
        "duration": 0.7
    },
    {
        "text": "Some of their work looks like traditional\nvaccine development,",
        "start": 13.64,
        "duration": 2.4
    },
    {
        "text": "albeit on a super sped up timeline.",
        "start": 16.049,
        "duration": 1.671
    },
    {
        "text": "But other research groups are trying some\nmore creative approaches",
        "start": 17.72,
        "duration": 2.35
    },
    {
        "text": "to therapy... including ones that involve\ndirectly editing our genes.",
        "start": 20.07,
        "duration": 3.56
    },
    {
        "text": "This is known as gene therapy, and it’s\nnot as outlandish",
        "start": 23.63,
        "duration": 2.73
    },
    {
        "text": "as you might be thinking.",
        "start": 26.36,
        "duration": 1.03
    },
    {
        "text": "The outlandish part is that viruses are one\nof our primary tools",
        "start": 27.39,
        "duration": 3.12
    },
    {
        "text": "for gene therapy -- meaning we might be able\nto solve",
        "start": 30.51,
        "duration": 2.38
    },
    {
        "text": "our current virus problem… with a virus.",
        "start": 32.89,
        "duration": 2.49
    },
    {
        "text": "However, this approach comes with some uncertainty",
        "start": 35.38,
        "duration": 2.27
    },
    {
        "text": "and a significant price tag, so it’s hardly\na sure thing.",
        "start": 37.65,
        "duration": 2.92
    },
    {
        "text": "Here’s how it might work.",
        "start": 40.57,
        "duration": 1.03
    },
    {
        "text": "The goal of a vaccine is to safely expose\nyour immune system",
        "start": 41.6,
        "duration": 2.981
    },
    {
        "text": "to antigens derived from an infectious agent\nlike a virus.",
        "start": 44.581,
        "duration": 3.809
    },
    {
        "text": "After vaccination, our bodies recognize this\nantigen",
        "start": 48.39,
        "duration": 2.919
    },
    {
        "text": "and know how to defend against it for a period\nof time.",
        "start": 51.309,
        "duration": 2.651
    },
    {
        "text": "That might mean exposing our bodies to a weakened",
        "start": 53.96,
        "duration": 2.14
    },
    {
        "text": "or inactivated form of a virus or bacterium\nso that our immune systems",
        "start": 56.1,
        "duration": 3.45
    },
    {
        "text": "can produce antibodies against it.",
        "start": 59.55,
        "duration": 1.73
    },
    {
        "text": "But there are plenty of other ways we can\nend up with immunity.",
        "start": 61.28,
        "duration": 2.5
    },
    {
        "text": "For example, some doctors are already using\nconvalescent plasma",
        "start": 63.78,
        "duration": 3.33
    },
    {
        "text": "from recovered patients to transfer their\nantibodies to patients",
        "start": 67.11,
        "duration": 3.24
    },
    {
        "text": "who are critically ill.",
        "start": 70.35,
        "duration": 1.01
    },
    {
        "text": "But that’s still in the testing stages.",
        "start": 71.36,
        "duration": 1.74
    },
    {
        "text": "Some of the vaccine candidates making swift\nprogress",
        "start": 73.1,
        "duration": 1.97
    },
    {
        "text": "in clinical trials are based on the nucleic\nacids DNA and RNA.",
        "start": 75.07,
        "duration": 4.32
    },
    {
        "text": "The idea is to teach our cells to make viral\nantigens and to show them",
        "start": 79.39,
        "duration": 3.61
    },
    {
        "text": "to our immune system -- rather than bundling",
        "start": 83.0,
        "duration": 2.04
    },
    {
        "text": "the antigens themselves in a shot.",
        "start": 85.04,
        "duration": 1.88
    },
    {
        "text": "One hurdle to this idea is getting that genetic\ncode into cells.",
        "start": 86.92,
        "duration": 3.62
    },
    {
        "text": "RNA, in particular, can get broken down pretty\nquickly in our bodies.",
        "start": 90.54,
        "duration": 3.13
    },
    {
        "text": "But the concept is solid: teach cells to make\na specific part",
        "start": 93.67,
        "duration": 3.04
    },
    {
        "text": "of the virus -- like the spike protein, which\nSARS-CoV-2",
        "start": 96.71,
        "duration": 3.46
    },
    {
        "text": "uses to invade our cells.",
        "start": 100.17,
        "duration": 1.21
    },
    {
        "text": "So rather than inject patients with just the\ncode,",
        "start": 101.38,
        "duration": 2.58
    },
    {
        "text": "another approach is more akin to fighting\nfire with fire.",
        "start": 103.96,
        "duration": 2.63
    },
    {
        "text": "Or a virus with a virus.",
        "start": 106.59,
        "duration": 2.06
    },
    {
        "text": "After all, viruses are really efficient at\ninjecting genetic material",
        "start": 108.65,
        "duration": 3.649
    },
    {
        "text": "into host cells.",
        "start": 112.299,
        "duration": 1.091
    },
    {
        "text": "It’s what they do -- they’re really just\nlittle nucleic acid",
        "start": 113.39,
        "duration": 2.681
    },
    {
        "text": "delivery packets, with instructions for making\nmore packets.",
        "start": 116.071,
        "duration": 2.599
    },
    {
        "text": "And we can reprogram those instructions.",
        "start": 118.67,
        "duration": 1.86
    },
    {
        "text": "So they’re actually perfect if we want to\nintroduce",
        "start": 120.53,
        "duration": 2.48
    },
    {
        "text": "genetic instructions into a cell.",
        "start": 123.01,
        "duration": 1.55
    },
    {
        "text": "But we need a virus that won’t also make\nus sick, which is why",
        "start": 124.56,
        "duration": 2.78
    },
    {
        "text": "adeno-associated viruses, or AAVs, are the\nDNA vehicle of choice.",
        "start": 127.34,
        "duration": 4.97
    },
    {
        "text": "AAVs are little viruses that don’t cause\ndisease,",
        "start": 132.31,
        "duration": 3.1
    },
    {
        "text": "further genetically engineered to deliver\ntheir payload",
        "start": 135.41,
        "duration": 2.189
    },
    {
        "text": "without making more of themselves.",
        "start": 137.599,
        "duration": 1.751
    },
    {
        "text": "They’ve already been used in the past in\nefforts",
        "start": 139.35,
        "duration": 2.24
    },
    {
        "text": "against other coronaviruses.",
        "start": 141.59,
        "duration": 1.67
    },
    {
        "text": "Different AAVs tend to infiltrate different\ntissues,",
        "start": 143.26,
        "duration": 2.83
    },
    {
        "text": "and since COVID-19 affects the lungs, we’d\nneed to find an AAV",
        "start": 146.09,
        "duration": 3.46
    },
    {
        "text": "that can get to our airway.",
        "start": 149.55,
        "duration": 1.43
    },
    {
        "text": "Some of the AAVs scientists have tested were\nable to get",
        "start": 150.98,
        "duration": 2.55
    },
    {
        "text": "into human respiratory cells in culture, but\nthey haven’t been tested",
        "start": 153.53,
        "duration": 3.2
    },
    {
        "text": "in actual humans yet.",
        "start": 156.73,
        "duration": 1.22
    },
    {
        "text": "And since an AAV is just a tiny DNA delivery\nunit, we could swap out",
        "start": 157.95,
        "duration": 3.98
    },
    {
        "text": "different sequences and test them all very\nquickly.",
        "start": 161.93,
        "duration": 2.47
    },
    {
        "text": "AAV-based gene therapy for other diseases\nhas already been approved",
        "start": 164.4,
        "duration": 3.29
    },
    {
        "text": "by the US Food and Drug Administration, which\ncould speed",
        "start": 167.69,
        "duration": 2.82
    },
    {
        "text": "implementation of a version of this therapy\nfor COVID,",
        "start": 170.51,
        "duration": 2.54
    },
    {
        "text": "at least according to some.",
        "start": 173.05,
        "duration": 1.0
    },
    {
        "text": "The potential downside is that this style\nof gene therapy",
        "start": 174.05,
        "duration": 3.47
    },
    {
        "text": "permanently edits cells.",
        "start": 177.52,
        "duration": 1.39
    },
    {
        "text": "Not as permanently as you might be thinking.",
        "start": 178.91,
        "duration": 1.72
    },
    {
        "text": "It wouldn’t target our germ cells, meaning\nwe wouldn’t pass",
        "start": 180.63,
        "duration": 2.34
    },
    {
        "text": "this DNA down to our kids.",
        "start": 182.97,
        "duration": 1.45
    },
    {
        "text": "We don’t yet know all of the cell types\nwe would need to target,",
        "start": 184.42,
        "duration": 3.1
    },
    {
        "text": "but the changes probably wouldn’t stay with\nus for a lifetime.",
        "start": 187.52,
        "duration": 2.689
    },
    {
        "text": "Which means any kind of AAV-based therapy\nwe develop for SARS-CoV-2",
        "start": 190.209,
        "duration": 3.451
    },
    {
        "text": "would only be a temporary fix.",
        "start": 193.66,
        "duration": 2.71
    },
    {
        "text": "But it might offer us some level of protection\nwhile we’re",
        "start": 196.37,
        "duration": 2.23
    },
    {
        "text": "waiting on a more permanent vaccine.",
        "start": 198.6,
        "duration": 1.58
    },
    {
        "text": "But we can’t rule out other long-term side\neffects",
        "start": 200.18,
        "duration": 2.169
    },
    {
        "text": "from directly tinkering with our DNA, even\nif it seems like",
        "start": 202.349,
        "duration": 3.051
    },
    {
        "text": "it should be safe based on what we know.",
        "start": 205.4,
        "duration": 2.2
    },
    {
        "text": "On top of all that, there’s the cost.",
        "start": 207.6,
        "duration": 2.54
    },
    {
        "text": "Since the currently approved AAV-based drugs\ntreat extremely rare",
        "start": 210.15,
        "duration": 3.4
    },
    {
        "text": "genetic diseases, they come with an inflated\nprice tag.",
        "start": 213.55,
        "duration": 3.409
    },
    {
        "text": "But since an AAV for COVID-19 would be a much\nlarger market,",
        "start": 216.959,
        "duration": 3.681
    },
    {
        "text": "the cost would hopefully be lower.",
        "start": 220.64,
        "duration": 1.83
    },
    {
        "text": "Now, will gene therapy for the novel coronavirus\never actually be a thing?",
        "start": 222.47,
        "duration": 4.489
    },
    {
        "text": "We have some good news on that front.",
        "start": 226.959,
        "duration": 1.541
    },
    {
        "text": "Researchers in Massachusetts recently announced\nplans",
        "start": 228.5,
        "duration": 1.86
    },
    {
        "text": "for a COVID vaccine clinical trial using AAVs.",
        "start": 230.36,
        "duration": 2.489
    },
    {
        "text": "They’re in the preclinical trials right\nnow, and if all goes well,",
        "start": 232.849,
        "duration": 3.39
    },
    {
        "text": "they’ll move into human trials later this\nyear.",
        "start": 236.239,
        "duration": 2.131
    },
    {
        "text": "Which means if we do ever see AAV therapy,\nit will still be a while.",
        "start": 238.37,
        "duration": 4.369
    },
    {
        "text": "But it’s definitely one of the more creative\nefforts out there",
        "start": 242.739,
        "duration": 1.98
    },
    {
        "text": "-- and we need to try everything we’ve got.",
        "start": 244.719,
        "duration": 2.701
    },
    {
        "text": "Thanks for watching this episode of SciShow,\nand thanks as always",
        "start": 247.42,
        "duration": 2.21
    },
    {
        "text": "to our amazing patrons.",
        "start": 249.63,
        "duration": 1.74
    },
    {
        "text": "Patrons not only make it possible for us to\nmake free videos",
        "start": 251.37,
        "duration": 2.21
    },
    {
        "text": "for everyone -- they also have access to cool\nbehind-the-scenes perks!",
        "start": 253.58,
        "duration": 3.279
    },
    {
        "text": "If you want to get involved, check out patreon.com/scishow.",
        "start": 256.86,
        "duration": 3.06
    },
    {
        "text": "[♪ OUTRO]",
        "start": 259.92,
        "duration": 10.44
    }
]